The company said that it will continue to seek funding for the SER-155 Phase 2 study.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%
The company said that it will continue to seek funding for the SER-155 Phase 2 study.